恒瑞医药：注射用卡瑞利珠单抗联合甲磺酸阿帕替尼片新适应症上市许可申请获受理

Core Viewpoint - Heng Rui Medicine announced that it and its subsidiary Suzhou Shengdiya Biopharmaceutical Co., Ltd. received a "Acceptance Notice" from the National Medical Products Administration for the new indication application of its innovative drug, injection Karilizumab combined with Apatinib, for the treatment of unresectable hepatocellular carcinoma [1] Group 1 - The new indication involves the use of injection Karilizumab in combination with Apatinib and transarterial chemoembolization (TACE) for treating unresectable hepatocellular carcinoma [1]